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REVIEW ARTICLE 
Antiretroviral therapy for drug users 
S M Clarke MB MRCPI and F M Mulcahy MD FRCPI 
Department of Genitourinary Medicine, St James’s Hospital, James’s Street, 
Dublin 8, Ireland 
Summary: Injection drug use represents the primary risk factor for up to 40% of patients with HIV infection. 
Physicians are generally reluctant to prescribe antiretroviral therapy (ART) for these patients due to possible poor 
adherence, and the potential for complex drug interactions to occur. Providing daily observed ART in conjunction 
with methadone maintenance therapy (MMT) has significantly improved accessibility of ART for many drug users. 
Knowledge of potential drug interactions between methadone, ART, and both legally and illegally prescribed drugs 
has permitted such interactions to be anticipated and either avoided or treated appropriately. Optimizing ART for 
drug users therefore demands a multidisciplinary approach from medical, clinical pharmacology and psychiatric 
services. 
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INTRODUCTION 
Injection drug use is the most common risk factor for the 
acquisition of HIV infection in Ireland, with drug users 
representing 42% of the total HIV-positive cohort1. In the 
USA, injection drug use represents the primary risk factor for 
22% of patients infected with HIV2. 
 For many active drug users, periods of daily heroin use 
are punctuated by cycles of detoxification drug treatment, and 
incarceration for drug-related offences. Dependent heroin 
abusers are at an increased risk of premature death from drug 
overdose, violence, disseminated infections, sub-acute 
bacterial endocarditis, and infectious diseases, none more so 
than HIV infection3. Highly active antiretroviral therapy 
(HAART) is now the standard of care for all patients with HIV 
infection, however physicians may be less likely to provide 
such treatment to drug users because of the belief that they are 
less adherent to complex regimens4. What has become 
increasingly clear is that adherence is essential to therapeutic 
effectiveness, and that a multidisciplinary effort is needed to 
meet the adherence challenge5. A study conducted at the AIDS 
Clinic in the San Francisco General Hospital showed a highly 
significant association between self report of missed doses and 
detectable viraemia6. Drug use, both former and current, are 
associated with higher levels of non-adherence7. The adverse 
effect that drug use may have on daily life patterns probably 
accounts more for this association. Recent studies showed that 
compared 
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with other risk groups, drug users were twice as likely not to 
be on HAART, and this increases to 3 times if they are not 
enrolled in a drug treatment unit8. Only 80% of drug users 
eligible for ART were receiving it, and only 37% of this group 
were 80% adherent with therapy8. 
 Furthermore, clinical trials tend to under-repre-sent 
minority groups such as injection drug users (IDUs), and may 
exclude those with chronic hepatitis B or C infection. There 
are therefore little data available on the long-term efficacy and 
tolerability of HAART for these patients. A further cause for 
concern for IDUs receiving HAART is the potential for 
complex drug interactions to occur. There are known 
significant interactions between antiretrovirals and 
methadone9, recreational drugs10, antipsychotics11, and other 
medications12. Such interactions must be clarified and their 
significance anticipated. 
 This paper reviews the active management of HIV 
infection in drug users, including linking HAART with MMT, 
suitable antiretroviral options and combinations, potential 
interactions between legally or illegally obtained drugs, 
potential interactions between methadone and antiretrovirals, 
and the role of co-infection with hepatitis C infection in these 
patients. 
METHADONE MAINTENANCE THERAPY 
Several studies have shown the efficacy of directly observed 
anti-tuberculosis therapy13, and the application of this method 
to ART is an attractive option for IDUs. Most current or ex-
IDUs attend methadone maintenance clinics on a daily basis. 
Methadone, a synthetic opioid was first reported as 
 
 
 
 
 
 
 
 
 
 
 
 
 
a treatment for opioid dependence by Dole and Nyswander in 
196514. The original model of high doses of methadone, long 
duration of treatment, and intensive rehabilitation services is 
still the most widely-used treatment for opioid dependence. 
Given in high doses, it reduces the craving for heroin/ and 
blocks the euphoric effects of injected heroin, thereby freeing 
the patient from the daily cycle of seeking out, buying, and 
using heroin. The exact daily dose of methadone is very 
variable, however a recent study shows that while both a 
moderate or high dose of methadone were effective in 
maintaining patients in treatment and substantially reducing 
rates of illicit opiate use, the high-dose group fared 
significantly better in all parameters15. 
DIRECTLY ADMINISTERED 
ANTIRETROVIRAL THERAPY (DAART) 
Once IDUs are stabilized from their opioid dependence, and 
attending a drug treatment clinic regularly, this is an ideal 
opportunity to introduce ART. We have found that IDUs are 
generally the first to acknowledge the erratic nature of their 
lifestyles, and are more than willing to participate in any 
programme that will minimize the impact on their lives of 
starting therapy. Adherence is the major determinant of the 
success of drug treatment—adherence of the physician in 
prescribing the optimum appropriate regimen and monitoring 
it, and compliance of the patient in taking the medication as 
prescribed. One way to ensure patient compliance is ‘directly 
observed therapy’ (DOT), where the ingestion of every drug 
dose is witnessed. The World Health Organization (WHO) 
DOTS strategy advocates the use of DOT with a short-course 
drug regimen for the treatment of tuberculosis16. Cohort 
studies with historical controls receiving self administered 
therapy have shown improved cure rates from DOT in a 
number of centres13,17. In the UK DOT is recommended for 
patients who are unlikely to comply e.g. homeless, alcoholic 
or drug abusers, patients with multiple drug resistances, or 
those with a history of non-compliance with anti-tuberculous 
therapy18, while in the USA, the Centers for Disease Control 
(CDC) recommends that DOT be considered for all patients19. 
Given the short- and long-term similarities between HIV and 
tuberculosis infection, with the association between 
inadequate compliance and the development of resistant 
strains, patients who are unlikely to adhere to ART should also 
be considered for DOT in the form of DAART. Such a 
programme of DAART linking MMT with HAART in the 
authors’ clinic has proved very successful in enrolling patients, 
with 37 patients commencing therapy since September 1998. 
However, results show that after an initial period of success, 
with 70% below the level of detection at 6 months, many 
IDUs default from both drug treatment and HIV clinics, with 
55% BLD (below the limit of detection: < 50 cpm Roche 
Ultrasensitive Assay) at one year, and only 25 of the original 
37 patients still attending20. These figures are consistent with 
one year success rates of 53-62% from methadone clinics for 
opioid detoxification21. An improved liaison system between 
both HIV and drug treatment services, involving 
multidisciplinary specialized clinics, specially trained nursing 
staff, and additional paramedical training for carers in the units 
may help to improve this outcome. 
HAART OPTIONS FOR IDUs 
The current International AIDS Society 2000 Guidelines for 
the treatment of HIV infection recommend dual nucleoside 
reverse transcriptase inhibitors (NRTIs) and either a protease 
inhibitor (PI) or a non-nucleoside reverse transcriptase 
inhibitor (NNRTI)22. If possible, ART should be prescribed to 
drug users in the form of once-daily therapy. This permits 
optimal adherence whether a patient is self-medicating or 
participating in a programme of DAART. At least 2 of the 
NRTIs (didanosine [ddI], lamivudine [3TC]) can be given 
once daily. ddI is licensed for use in HIV-infected patients in a 
twice-daily regimen. However the long intracellular half-life 
of dideoxyadenosinetriphosphate (ddATP) (8-40 h in cell 
culture studies23), has been the basis of more formal studies 
showing that once-daily dosing of ddI leads to a similar 
exposure in plasma as twice-daily dosing24. The serum 
elimination half-life of lamivudine is approximately 2.5 h, and 
the in vitro intracellular half-life of its active 5-triphosphate 
anabolite is 11-14 h25. Therefore a once-daily dosing of 3TC is 
pharmacologically adequate. The other NRTIs require twice-
daily dosing. The currently available PIs require either twice 
or three times daily dosing. The prolonged half-lives of 
nevirapine (NVP) and efavirenz (EFV) (25 and 45 h 
respectively) permit once-daily dosing26,27. 
 Other drugs in early development e.g. MK944A, 
tenofovir, have long half-lives, which should permit once-
daily dosing. A new PI, BMS232632, is currently in phase III 
trials and should acquire a license for once-daily dosing. The 
combination antiretroviral pill that includes zidovudine (AZT), 
3TC, and abacavir (ABC) is also in phase III trials, and will 
allow a convenient one pill twice-daily dosing. Initial studies 
have shown comparable 48-week results for this combination 
to a dual nucleoside with indinavir regimen28. 
HAART AND PSYCHIATRIC MEDICATIONS 
If psychiatric illness and drug addiction are uncontrolled, 
medication adherence may be compromised. Studies suggest a 
rate as high as 50% co-morbidity in HIV-positive patients in 
inner city clinics29. Co-morbid substance use is the most 
powerful predictor of psychiatric illness. Psycho-tropic 
medications, including anti-depressants, neuroleptics, and 
anti-convulsants are often pre-scribed for patients to manage 
drug or disease-related adverse events, for mood stabilizing 
effects, for concurrent psychiatric conditions. Such 
medications often have narrow therapeutic indices, and may 
be susceptible to interactions involving the cytochrome P450 
enzyme system. Ritonavir (RTV) inhibits numerous CYP450 
enzymes (3A4, 2D6, 2C9, 2C19, 2A6, 1A2, 2E1), and has the 
Greatest potential for significant interactions with 
psychotropic medications30. Such medications that are 
contraindicated with RTV include bupropion, clozapine, and 
pimozide11. RTV also has the potential to significantly 
increase serum concentrations of the tricyclic anti-depressants 
(TCADs), selective serotonin reuptake inhibitors (SSRIs), and 
the phenothiazines. It is recommended that the dose of such 
drugs is reduced by 50% with close monitoring of toxicity if 
they are co-prescribed11. Saquinavir (SQV), nelfinavir (NFV), 
indinavir and the NNRTIs are primarily CYP 3A4 inducers, 
and while their effect on psychotropic medications is less 
significant, they may still alter therapeutic levels. 
 Anti-convulsants are mainly CYP 3A4 inducers, and 
drugs such as carbamazepine, phenytoin, and phenobarbitone, 
should be avoided where possible31, as they may lead to sub-
therapeutic levels of antiretrovirals. Detailed tables outlining 
potential interactions are available and should be consulted 
prior to co-prescribing antiretrovirals and psycho-tropics11,32. 
HAART AND METHADONE: NNRTIs 
Efavirenz and NVP are very useful drugs for the treatment of 
IDUs due to convenient once-daily dosing. Both drugs are 
potent inducers of the CYP 450 enzyme system, which is the 
primary pathway through which methadone is 
metabolized26,27. A significant interaction between these 
medications, with a mean reduction in AUCo-24h methadone 
of 60% has been demonstrated. During the initial period of 
treatment, there appears to be a process of ‘induction-
detoxification’ whereby the increased dose of methadone 
required is not as great as might be expected from the PK data. 
The mean dose required was 21.65%, with a mean time for 
symptoms of withdrawals of 7-10 days9. 
HAART AND METHADONE: PIs 
The potential for an interaction between the PIs and 
methadone is less clear, with some conflicting reports. PIs in 
general inhibit CYP3A4, RTV most potently, IDV, NFV, SQV 
less intensely12. Initial studies suggested that RTV may retard 
methadone metabolism33, however a further study, flawed due 
to the inclusion of patients not dependent on methadone, with 
patients receiving only 5-10 mg daily, did not show similar 
results34. There have been reports of both NFV-induced 
methadone withdrawal35, and NFV-induced reduction in 
AUC0-24h methadone, but without inducing symptoms of 
methadone withdrawal36. Further studies are clearly needed to 
further define this interaction. 
HAART AND METHADONE: NRTIs 
There have been few studies looking at the interaction 
between methadone and the NRTIs. Methadone has been 
demonstrated to increase the AUC for AZT by approximately 
40%37. To date there are no studies demonstrating an increased 
incidence of AZT-related toxicities in such patients i.e. 
myelosuppression, fatigue, myalgia. Another study has shown 
a mean reduction in the AUC for ddI of 60% when methadone 
was co-prescribed38. The aetiology of such an affect was 
hypothesized as altered gastrointestinal absorption. However, 
this study measured serum ddI levels and not the active 
triphosphate metabolite. More studies are needed to clearly 
define whether the dose of ddI needs to be increased in such 
patients receiving methadone and ddI. 
OTHER DRUGS AND METHADONE 
For patients on MMT receiving concurrent fluco-nazole, an 
inhibitor of CYP 450, a mean increase in the systemic 
methadone exposure of 34.8% has been demonstrated, 
however no signs or symptoms of methadone overdose were 
demonstrated during the study, and no patients complained of 
methadone withdrawal during the post-study period39. IDUs 
are at an increased risk of acquiring tuberculosis and the 
association between rifampi-cin and reduced effectiveness of 
methadone has been well described40. In a cohort of 30 
patients receiving methadone and rifampicin 70% of patients 
required an increase in their methadone dose, with the onset of 
withdrawal symptoms from 1-33 days after the initiation of 
therapy40. There have been other similar reports of this 
interaction, and the requirement for additional methadone in 
such patients41,42. 
RECREATIONAL DRUGS 
There are a wide range of recreational drugs used by drug 
users, including inhaled, injected, and orally taken substances. 
While there is a large database on the interactions between 
antiretrovirals and legally prescribed medications12, there are 
little published data on interactions between antiretrovirals and 
illicit substances. Amphetamines are generally metabolized to 
active metabo-lites through the CYP 2D6 isoform of the CYP 
450 system. There have been reports of a prolonged effect 
from a small dose of methylenedioxymetam-phetamine 
(MDMA or ecstasy), and a nearly fatal reaction to a small dose 
of y-Hydrobutyrate (GHB) in a patient receiving RTV and 
SQV10. This interaction is probably CYP 450 mediated, with 
RTV delaying the metabolism of both of these substances, 
prolonging their effect. 
 The benzodiazepines are primarily metabolized by CYP 
3A4 and CYP 2C19. There is therefore a potential significant 
interaction with the PIs enhancing their effects via inihibition 
of these enzymes, and the NNRTIs reducing their effect via 
enzyme induction. 
 Cocaine is metabolized by hydrolysis by plasma 
cholinesterase and there is no interaction with antiretrovirals. 
Morphine, hydromorphine, and heroin are metabolized by 
glucuronidation, and there is a potential for induction of this 
process by PIs. Dextropropoxyphene and meperidine are 
metabolized by CYP450, and there is significant production of 
toxic metabolites if these are co-administered with PIs. 
HEPATITIS C CO-INFECTION 
The incidence of hepatitis C co-infection in IDUs is 80-90%43. 
Recent papers have demonstrated hepa-totoxicity associated 
with ART, especially RTV44. While this has been shown to be 
more common in patients with chronic hepatitis, the evidence 
to date does not support withholding PI therapy from persons 
co-infected with hepatitis B or C viruses. There have been no 
similar published data regarding the NNRTIs. 
 There have been numerous conflicting reports of both 
reduced and increased hepatitis C viral load during HAART 
therapy45-48, and also of re-activation of hepatitis C infection 
during HAART therapy49. 
 In conjunction with the improved outlook for HIV and 
hepatitis C co-infected patients, some of the emphasis of their 
management involves the active management of their hepatitis 
C infection. The long-term therapy of choice appears to 
involve combination therapy with ribavirin and interfer-on50,51. 
As ribavirin and the nucleoside analogues undergo 
intracellular activation to the active moiety, i.e. triphosphate, 
the potential for a drug interaction arises. Results published by 
our group have demonstrated the ability of ribavirin to 
influence the intracellular phosphorylation of the nucleosides 
AZT and ddI in vitro52,53. 
 It is essential that the potential intracellular 
phosphorylation interaction involving ribavirin and the 
nucleoside analogues be determined prior to the introduction 
of hepatitis C therapy in the clinical setting, as this may have 
implications on the efficacy and the toxicity of these agents. If 
the in vitro inhibitory effect of ribavirin is significant, this 
could lead to a reduction in nucleoside analogue intracellular 
triphosphate resulting in reduced efficacy. This could be 
coupled with increased monophosphate drug levels, enhancing 
toxicity. 
CONCLUSION 
While combination ART has proven to be effective in slowing 
disease progression, the long-term benefits of these therapies 
can only be sustained if resistance strains of HIV do not 
emerge. Adherence to HAART is a critical component of such 
a successful outcome. IDUs are less likely to receive HAART 
than other risk groups and are less adherent with complex drug 
regimens. Strategies to improve this situation include novel 
ways of prescribing medications (i.e. DAART), choosing 
simple once- or twice-daily regimens, and anticipating, 
monitoring, and treating potential drug interactions. 
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